Revance Therapeutics Inc
(NAS:RVNC)
$
3.04
-0.02 (-0.65%)
Market Cap: 317.35 Mil
Enterprise Value: 618.80 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 67/100 Revance Therapeutics Inc at Morgan Stanley Healthcare Conference Transcript
Sep 10, 2019 / 08:40PM GMT
Release Date Price:
$12.55
(+11.36%)
Unidentified Analyst
All right. So thanks, everyone, for joining this session with Revance. I just need to mention our disclaimer upfront that we need to refer to you www.morganstanley.com/researchdisclosures. It's very much my pleasure to welcome Dan Browne, the CEO of Revance. He is actually one of the cofounders and has more than 25 years of executive leadership experience across biopharmaceuticals and medical technology. So thank you very much for joining us, Dan.
L. Daniel Browne
Revance Therapeutics, Inc. - Co-Founder, President, CEO & Director
Thank you, David.
Questions & Answers
Unidentified Analyst;L. Daniel Browne
I guess it would be great for you to start with your vision for Revance. Obviously, you've achieved a lot particularly in the past year or so but how you see the company evolving going forward? And then we can get into some more details on execution and events to watch.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot